Finally, in the phase III JAVELIN Lung 200 trial, the PD-L1 inhibitor avelumab was compared to docetaxel in patients with previously treated PD-L1 positive advanced NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.